poisar

Stocks · News reference

Dassault Systemes Affirms FY2026 Adj EPS Guidance of $1.52-$1.57 vs $1.54 Est; Affirms FY2026 Sales Guidance of $7.366B-$7.506B vs $7.410B Est

Jul 23, 2026, 7:57 AMBenzinga Newsdesk

Dassault Systemes (OTC:DASTY) affirms FY2026 Adj EPS guidance from $1.52-$1.57 to $1.52-$1.57 vs $1.54 analyst estimate. Affirms FY2026 sales outlook from $7.366 billion-$7.506 billion to $7.366 billion-$7.506 billion

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

DASTY
Source
benzinga
Observed
Jul 23, 2026, 7:57 AM
Checked
Jul 23, 2026, 7:57 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Jul 23, 2026, 4:57 AMNa

    Dassault Systèmes to acquire ArisGlobal, creating a unified AI intelligence platform for the Life Sciences industry connecting molecule, patient and real-world outcomes

    Dassault Systèmes announced the acquisition of ArisGlobal for approximately $1.8 billion in cash plus up to $200 million in milestone-based consideration. The deal combines ArisGlobal's AI-native compliance platform serving 200+ customers with Dassault Systèmes' domain expertise in drug discovery and manufacturing, creating a unified intelligence platform for the Life Sciences industry. The transaction is expected to close in H2 2026 and be accretive to revenue growth and EPS in Year 1.

    Read original at globenewswire-inc
    DASTY
  3. Jul 23, 2026, 4:57 AMDassault Systèmes

    Dassault Systèmes acquiert ArisGlobal pour créer une plateforme d’IA unifiée pour les Sciences de la vie, reliant molécule, patient et résultats du monde réel

    Dassault Systèmes announced the acquisition of ArisGlobal for approximately $1.8 billion in cash, plus up to $200 million in performance-based earnouts. The deal combines Dassault's expertise in R&D, clinical development, and manufacturing with ArisGlobal's AI-native compliance platform serving over 200 life sciences clients. The acquisition is expected to be accretive to earnings per share in the first year and create a unified AI intelligence platform for the life sciences industry.

    Read original at globenewswire-inc
    DASTY